Your browser doesn't support javascript.
loading
Lighting the way to host-directed immunotherapeutics.
van Tol, Sarah; Hage, Adam; Rajsbaum, Ricardo.
Afiliação
  • van Tol S; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address: savantol@utmb.edu.
  • Hage A; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address: arhage@utmb.edu.
  • Rajsbaum R; Center for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, NJ, USA. Electronic address: ricardo.rajsbaum@rutgers.edu.
Cell Chem Biol ; 29(7): 1067-1070, 2022 07 21.
Article em En | MEDLINE | ID: mdl-35868235
ABSTRACT
Developing broad-spectrum, host-directed antiviral therapeutics can be adapted to combat emerging viruses. In this issue of Cell Chemical Biology, Maarifi and colleagues implement a Nano luciferase reporter-based protein complementation assay to screen for small molecules and identify Gilteritinib, which enhances interferon induction and antagonizes virus replication.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Replicação Viral Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Replicação Viral Idioma: En Ano de publicação: 2022 Tipo de documento: Article